RANBP2-ALK rearrangement + TNFRSF8 expression
|
Fibrosarcoma
|
RANBP2-ALK rearrangement + TNFRSF8 expression
|
Fibrosarcoma
|
ceritinib + brentuximab vedotin Sensitive: D – Preclinical
|
ceritinib + brentuximab vedotin Sensitive: D – Preclinical
|
RANBP2-ALK rearrangement + TNFRSF8 expression
|
Fibrosarcoma
|
RANBP2-ALK rearrangement + TNFRSF8 expression
|
Fibrosarcoma
|
crizotinib + brentuximab vedotin Sensitive: D – Preclinical
|
crizotinib + brentuximab vedotin Sensitive: D – Preclinical
|
RANBP2-ALK rearrangement + TNFRSF8 expression
|
Sarcoma
|
RANBP2-ALK rearrangement + TNFRSF8 expression
|
Sarcoma
|
brentuximab vedotin Resistant: D – Preclinical
|
brentuximab vedotin Resistant: D – Preclinical
|